|
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
RECRUITINGPhase 2Sponsored by Frantz Viral Therapeutics, LLC
Actively Recruiting
PhasePhase 2
SponsorFrantz Viral Therapeutics, LLC
Started2020-09-09
Est. completion2026-07-31
Eligibility
Age25 Years – 100 Years
SexFEMALE
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT04098744
Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Eligibility
Age: 25 Years – 100 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria: * Adult females age ≥ 25 years * Capable of informed consent * Any HPV genotype detectable by DNA test/HPV genotyping * Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3) * Women of childbearing potential agree to use birth control through week17 of the study. * Weight ≥ 50kg Exclusion Criteria: * Pregnant and nursing women * Active autoimmune disease * Taking immunosuppressive medication * HIV seropositivity * Immunocompromised subjects * Evidence of concurrent cervical adenocarcinoma in situ * Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects
Conditions6
CIN 2/3CancerCervical DysplasiaHPV InfectionHPV Related DiseasePre-Cancerous Dysplasia
Locations7 sites
Florida Gynecologic Oncology
Fort Myers, Florida, 33905
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorFrantz Viral Therapeutics, LLC
Started2020-09-09
Est. completion2026-07-31
Eligibility
Age25 Years – 100 Years
SexFEMALE
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT04098744